BG
XENE icon

Bellevue Group’s Xenon Pharmaceuticals XENE Stock Holding History

Bellevue Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,200
Closed -$321K – 169
2024
Q4 		$321K Hold
8,200
– – 0.01% 134
2024
Q3 		$323K Sell
8,200
-2,000
-20% -$80.6K 0.01% 137
2024
Q2 		$398K Sell
10,200
-3,900
-28% -$156K 0.01% 134
2024
Q1 		$607K Sell
14,100
-7,900
-36% -$363K 0.01% 126
2023
Q4 		$1.01M Sell
22,000
-1,900
-8% -$67.1K 0.02% 121
2023
Q3 		$816K Hold
23,900
– – 0.01% 135
2023
Q2 		$920K Buy
+23,900
New +$950K 0.01% 131

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bellevue Group's XENE Position: Q1 2025 in Review

Bellevue Group sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 8,200 shares — an estimated $321K sold.

Bellevue Group first reported a position in XENE in Q2 2023 and held it in 7 quarters. The position peaked at $1.01M in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Bellevue Group reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 8,200 Xenon Pharmaceuticals shares in Q1 2025, an estimated $321K.
  • Bellevue Group first reported a position in Xenon Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Bellevue Group's Xenon Pharmaceuticals position peaked at $1.01M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.